ResMed to Announce Third Quarter Fiscal Year 2018 Results

SAN DIEGO--()--ResMed (NYSE: RMD) today announced it will report its third quarter of fiscal year 2018 results on Thursday, April 26, 2018, after the New York Stock Exchange market closes. A press release with ResMed’s results will be issued after 1:00 p.m. US Pacific Time and the company will host a webcast to discuss operating results and future outlook.

The earnings webcast is scheduled to begin at 1:30 p.m. US Pacific Time and the live webcast of the call can be accessed on ResMed's Investor Relations website at investor.resmed.com. Please go to this section of the website and click on the icon for the “Q3 2018 earnings webcast.”

Please note that we do not use outside phone lines to access the earnings call.

International earnings webcast times will be:

Thursday, April 26, 9:30 p.m. London
Friday, April 27, 6:30 a.m. Sydney

A replay of the earnings webcast will be accessible on our website and available approximately two hours after the webcast. In addition, a phone replay will be available approximately two hours after the webcast and will be accessible from April 26, 2018, until May 10, 2018, at:

US: +1 800-585-8367
Outside US: +1 416-621-4642
Passcode: 7899017

About ResMed

ResMed (NYSE: RMD) (ASX: RMD), a world-leading connected health company with more than 4 million cloud-connected devices for daily remote patient monitoring, changes lives with every breath. Its award-winning devices and software solutions help treat and manage sleep apnea, chronic obstructive pulmonary disease and other respiratory conditions. Its 6,000-member team strives to improve patients’ quality of life, reduce the impact of chronic disease and save healthcare costs in more than 120 countries. ResMed.comFacebookTwitter | LinkedIn

Contacts

ResMed
For media
Jayme Rubenstein
858-836-6798
news@resmed.com
or
For investors
David Pendarvis
O: 858-836-5983
investorrelations@resmed.com

Contacts

ResMed
For media
Jayme Rubenstein
858-836-6798
news@resmed.com
or
For investors
David Pendarvis
O: 858-836-5983
investorrelations@resmed.com